Priors rates this Likely — 74 out of 100, updated weekly. Probably — but it is not fully settled. On the claim that lorlatinib improves PFS vs alectinib in ALK+ NSCLC, its four-agent AI review panel weighs 5 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full ALK and ROS1 Inhibitors review.